8-K: Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio is on track to initiate dosing in the RLYB116 confirmatory PK/PD study in 2Q 2025, with multiple data readouts anticipated in 2H 2025, and holds $54.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing runway into 1H 2027.

Summary

• Rallybio reported its first quarter 2025 financial results on May 8, 2025.
• The company is focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study in the second quarter of 2025.
• Rallybio believes data from this study will demonstrate RLYB116's potential as a best-in-class therapeutic for complement-driven diseases.
• The company's preclinical pipeline includes REV102 and RLYB332.
• Dosing in the RLYB116 confirmatory clinical PK/PD study is on track to begin in the second quarter of 2025.
• Results from Cohort 1 (150 mg once weekly) and Cohort 2 (225 mg once weekly) are anticipated in the third and fourth quarter of 2025, respectively.
• IND-enabling studies are underway for REV102, with a Phase 1 study expected to begin in the second half of 2026.
• Data evaluating REV102 in a preclinical model of later-onset HPP is expected in the second half of 2025.
• Rallybio continues to evaluate plans for future development of RLYB332.
• In April 2025, Rallybio discontinued the RLYB212 program due to unfavorable PK data.
• Rallybio is implementing a 40% workforce reduction, representing nine positions, substantially complete by the end of the second quarter of 2025.
• The workforce reduction is estimated to result in charges of approximately $1.7 million.
• Revenue for the first quarter of 2025 was $0.2 million.
• R&D expenses were $5.7 million for the first quarter of 2025.
• G&A expenses were $4.2 million for the first quarter of 2025.
• Rallybio reported a net loss of $9.4 million, or $0.21 per common share, for the first quarter of 2025.
• As of March 31, 2025, cash, cash equivalents, and marketable securities were $54.5 million.
• Rallybio expects these funds will be sufficient to support operations into the first half of 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress with RLYB116 and has a decent cash runway, the discontinuation of RLYB212 and the workforce reduction are negative factors. The financial results show a net loss, but improvements compared to the previous year temper the negative outlook.

Positives

• Rallybio is on track to initiate dosing in the RLYB116 confirmatory PK/PD study in 2Q 2025.
• The company has a cash runway into the first half of 2027 with $54.5 million in cash, cash equivalents, and marketable securities.
• Revenue increased to $0.2 million for the first quarter of 2025 due to the collaboration agreement with Johnson & Johnson.
• R&D and G&A expenses decreased compared to the same period in 2024.
• Net loss per common share decreased from $0.47 in Q1 2024 to $0.21 in Q1 2025.

Negatives

• Rallybio discontinued the RLYB212 program due to unfavorable PK data.
• The company is implementing a 40% workforce reduction.
• The workforce reduction will result in aggregate charges of approximately $1.7 million.
• Rallybio reported a net loss of $9.4 million for the first quarter of 2025.

Risks

• The success of the RLYB116 program is dependent on the results of the confirmatory PK/PD study.
• The development of REV102 and RLYB332 is subject to the risks and uncertainties associated with preclinical and clinical development.
• Competition from other biotechnology and pharmaceutical companies could impact the commercial potential of Rallybio's product candidates.
• The company's cash runway is dependent on its ability to manage expenses and potentially raise additional capital.

Future Outlook

Rallybio expects to initiate dosing in the RLYB116 confirmatory PK/PD study in the second quarter of 2025 and anticipates multiple data readouts in the second half of 2025. The company expects its current cash, cash equivalents, and marketable securities to be sufficient to support operations into the first half of 2027.

Management Comments

• We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe that data from this study will demonstrate RLYB116s potential to be a best-in-class therapeutic for patients with complement-driven diseases, said Stephen Uden, M.D., Chief Executive Officer of Rallybio.
• Leveraging our teams deep expertise in the complement field, we are well-positioned to maximize RLYB116s transformative potential across multiple billion-dollar market opportunities.
• Additionally, we believe significant value resides within our preclinical pipeline, which includes REV102 and RLYB332.
• By advancing our innovative pipeline, we are committed to creating exceptional value for our shareholders while delivering life-changing therapies to patients who need them most.

Industry Context

Rallybio is operating in the competitive biotechnology industry, focusing on rare diseases and unmet medical needs. The company's focus on complement dysregulation, hematology, and metabolic disorders aligns with areas of significant research and development activity in the pharmaceutical sector. The collaboration with Johnson & Johnson indicates industry interest in Rallybio's programs.

Comparison to Industry Standards

• Rallybio's focus on rare diseases aligns with companies like BioMarin Pharmaceutical and Alexion Pharmaceuticals (now part of AstraZeneca), which have successfully developed and commercialized therapies for rare conditions.
• The development of a C5 inhibitor (RLYB116) places Rallybio in competition with companies like Alexion, which markets Soliris and Ultomiris, both C5 inhibitors.
• The workforce reduction of 40% is a significant restructuring, which is not uncommon in the biotech industry when companies need to prioritize programs or manage cash flow; similar restructurings have been seen at companies like Unum Therapeutics and Agenus in the past.
• The cash runway into the first half of 2027 is a positive sign, but it's crucial to compare this to the burn rate of similar-stage biotech companies to assess its adequacy; companies like Generation Bio and LogicBio Therapeutics provide relevant benchmarks.

Stakeholder Impact

• Shareholders will be impacted by the discontinuation of the RLYB212 program and the workforce reduction.
• Employees will be affected by the 40% workforce reduction.
• Patients may benefit from the continued development of RLYB116, REV102, and RLYB332.
• The company's financial performance and strategic decisions may impact its relationships with suppliers and creditors.

Next Steps

• Initiate dosing in the RLYB116 confirmatory clinical PK/PD study in the second quarter of 2025.
• Obtain results from Cohort 1 and Cohort 2 of the RLYB116 study in the third and fourth quarters of 2025, respectively.
• Continue IND-enabling studies for REV102.
• Potentially initiate a Phase 1 study for REV102 in the second half of 2026.
• Present data evaluating REV102 in a preclinical model of later-onset HPP in the second half of 2025.
• Continue to evaluate plans for future development of RLYB332.
• Substantially complete the workforce reduction by the end of the second quarter of 2025.

Key Dates

Keywords

RLYB116, REV102, RLYB332, RLYB212, Rallybio, Financial Results, Biotechnology, Rare Diseases, Clinical Stage, PK/PD Study, Workforce Reduction, Cash Runway, Complement Dysregulation, Hematology, Metabolic Disorders